FD TORIAL

he journal *Biomarkers* has now completed its first year of operation. By all our criteria it has been successful. Thus there is a steady flow of manuscripts of high quality and there is a healthy and increasing number of subscribers. The feedback I have had from editorial board members and others working in the field of biomarkers so far has been very positive. In the first issue I said that launching a new journal was fraught with uncertainty. We have passed the first stage of uncertainty and vindicated the belief that there is indeed a need for a journal to cover the area of biomarker research and development and Biomarkers has filled the niche. Manuscripts have so far been received from 22 countries, with the majority from the USA. The area continues to increase in interest and importance. The manuscripts have covered a wide range of topics from studies in humans to various other animal species in their natural habitats. I would however like to see more manuscripts in the area of biomarkers of susceptibility. The next stage is to consolidate on this successful beginning and maintain, and I hope increase, the supply of allow abscribers. The number of good manuscripts this first year has been enough to allow a move to bimonthly publication, build be good for authors who will see a reduction in publication time and subscribers who will get more articles per year as a result of the increased number of pages.

Authors are encouraged to submit their revised manuscripts on diskette as well as hard copy and this should help speed up the publication process.

We hope in future issues to include special items such as those resulting from conference proceedings and intend to maintain the inclusion of reviews.

Biomarkers is now available on-line. Issues will be available up to 6 weeks before they appear in print. with uncertainty. We have passed the first stage of

Biomarkers is now available on-line. Issues will be available up to 6 weeks before they appear in print. Contact Taylor & Francis by sending an email to online@tandf.co.uk for details.

Finally I would like to thank all the reviewers of manuscripts, both those who are members of the editorial board and those who are not (whose names appear below). The reviews have generally been thorough and returned rapidly. Both these factors help the journal establish a good reputation. Thanks also to those authors who have submitted good quality manuscripts or those who have encouraged others to do so. Submitting your work to a new journal is always a risk because of limited exposure. Consequently I encourage all authors to mail their reprints to those

colleagues working in the same area. In this way the journal will become more widely known.

A free service has been introduced to enable anyone to receive Contents pages from Biomarkers before the journal appears in print. To receive details of how to subscribe to this service send an email message to mailserve@tandf.co.uk leaving the subject heading blank, and with the following message:

LISTS

END.

I look forward to another successful year for the journal.

Editor

Thanks to the following for the time they have spent reviewing manuscripts for volume 1:

Dr J. Boon, The Netherlands

Dr N. Browne, UK

Professor J. P. Buchet, Belgium

Dr J. Cocker, UK

Dr D. Cooper, UK

Dr D. Creasy, UK

Professor J. Descotes, France

Professor R. T. Di Giulio, USA

Dr H. Evans, USA

Dr K. Gartland, UK

Dr D. Grant, Canada

Dr C. Hermans, Belgium

Dr K. Hylland, Norway

Dr K. Jakobsson, Sweden

Dr Jiankang Liu, USA

Dr A. Jenner, UK

Dr A. Kortenkamp, UK

Dr P. Lindström-Seppä, Finland

Dr E. Martin, UK

Professor A. Mutti, Italy

Dr K. Peltonen, Finland

Dr V. R. Preedy, UK

Dr M. Raffray, UK

Professor D. Schlenk, USA

Dr R. F. Shore, UK

Dr D. E. G. Shuker, UK

Professor T. G. Smart, UK

Professor R. Strange, UK

Dr P. Toniolo, USA

Dr J. H. M. van Delft, The Netherlands

Dr I. I. Wirgin, USA